A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
NCT05696847
Completed
The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 13 weeks excluding the screening period.
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
02/21/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Obesity
Register for Updates
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
NCT06246799
Recruiting
The primary purpose of this study is to evaluate the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide compared to metformin plus sitagliptin in patients with recently diagnosed type 2 diabetes mellitus.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/20/2025
Locations: University Health System Texas Diabetic Institute, San Antonio, Texas +1 locations
Conditions: Type 2 Diabetes (Adult Onset)
Register for Updates
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
NCT06737042
Not Yet Recruiting
This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-related comorbidities (excluding type 2 diabetes mellitus).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/03/2025
Locations: Elligo Clinical Research Center - Austin, Austin, Texas +2 locations
Conditions: Obesity and Overweight
Register for Updates
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
NCT04166773
Completed
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/22/2025
Locations: Dallas Diabetes Research Center, Dallas, Texas +7 locations
Conditions: Nonalcoholic Steatohepatitis
Register for Updates
A Study of LY3841136 in Overweight and Obese Participants
NCT06345066
Active Not Recruiting
The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/21/2025
Locations: Fortrea Clinical Research Unit, Dallas, Texas
Conditions: Obesity, Overweight
Register for Updates
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
NCT06732245
Not Yet Recruiting
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
Gender:
ALL
Ages:
Between 19 years and 80 years
Trial Updated:
12/12/2024
Locations: Biomed Research Unit # 77479-108, Sugar Land, Texas
Conditions: Obesity and Overweight
Register for Updates
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
NCT05706506
Completed
The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in participants with type 2 diabetes (T2D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Texas Diabetes & Endocrinology, P.A., Austin, Texas +4 locations
Conditions: Type 2 Diabetes, Diabetes Mellitus, Type 2
Register for Updates
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
NCT05822830
Completed
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: The University of Texas Health Science Center at Houston, Bellaire, Texas +6 locations
Conditions: Obesity, Overweight
Register for Updates
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
NCT06517212
Recruiting
This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the growth and survival of micrometastatic disease and leading to clearance of tumor-informed circulating tumor DNA (ctDNA) and freedom from the development of metastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas
Conditions: Breast Cancer, Breast Neoplasms, Breast Cancers
Register for Updates
A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices
NCT05810597
Completed
The main purpose of this study is to look at the amount of the study drug, tirzepatide, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of tirzepatide and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 14 weeks, including screening.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/17/2024
Locations: ICON Early Phase Services, San Antonio, Texas
Conditions: Healthy
Register for Updates
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
NCT04660643
Completed
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which participants either continued tirzepatide or switched to placebo. The study lasted about 2 years (25 visits).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: The University of Texas Health Science Center at Houston, Bellaire, Texas +6 locations
Conditions: Obesity, Overweight
Register for Updates
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
NCT04657016
Completed
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Dallas Diabetes Research Center, Dallas, Texas +4 locations
Conditions: Obesity, Overweight
Register for Updates